As of May 31, 2025, Pluristem Therapeutics Inc (PSTI) reports a ROE (Return on Equity) of 87.26%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Pluristem Therapeutics Inc's ROE (Return on Equity)
Over recent years, Pluristem Therapeutics Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-06-30 | 87.26% |
| 2020-06-30 | -51.96% |
| 2019-06-30 | -161.82% |
| 2018-06-30 | -91.65% |
| 2017-06-30 | -91.93% |
This slight upward trend highlights how Pluristem Therapeutics Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Pluristem Therapeutics Inc's ROE (Return on Equity) to Peers
To better understand Pluristem Therapeutics Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Pluristem Therapeutics Inc (PSTI) | 87.26% |
| Nymox Pharmaceutical Corp (NYMX) | 1364.32% |
| Evaxion Biotech A/S (EVAX) | 639.65% |
| Brainstorm Cell Therapeutics Inc (BCLI) | 149.70% |
| Kamada Ltd (KMDA) | 5.57% |
| Aileron Therapeutics Inc (ALRN) | -16.00% |
Compared to its competitors, Pluristem Therapeutics Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.